Astraveus

Astraveus develops Lakhesys, an end-to-end cell foundry platform that transforms cell and gene therapy (CGT) manufacturing through miniaturization and automation. The platform employs deep process optimization and single-use microfluidic bioprocessors that mimic organ perfusion to accelerate molecular exchanges needed to transform cells into therapeutic agents. The microfluidic technology enables efficient manufacturing by reducing labor, floor space, and energy requirements while minimizing waste. The Lakhesys platform addresses the challenge of high production costs in CGT manufacturing, which can reach up to USD 2 million per patient. By minimizing changes between process development and clinical applications while offering modular scalability, the system aims to transform both clinical research and manufacturing of approved products.

The technology enhances precision in manufacturing through its scaled-down approach, where reducing size by a factor of 10 increases molecular exchange and mass transfer by 100 times. This leads to faster and more efficient manufacturing processes while maintaining single-use processing to prevent cross-contamination. The company's platform is designed to be more environmentally sustainable due to its reduced resource consumption and waste generation compared to traditional manufacturing methods.